Novel developments in the epidemic of human immunodeficiency virus and tuberculosis coinfection

American Journal of Respiratory and Critical Care Medicine

Volumn 183, Issue 8, 2011, Pages 987-997

  Anandaiah, Asha ^a   Dheda, Keertan ^b,c   Keane, Joseph ^d   Koziel, Henry ^a   Moore, David A J ^e   Patel, Naimish R ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d TRINITY COLLEGE DUBLIN   (Ireland)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Diagnosis; Epidemiology; HIV; Management; Tuberculosis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BCG VACCINE; EFAVIRENZ; ETHAMBUTOL; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; ISONIAZID; LOPINAVIR; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR;

ADAPTIVE IMMUNITY; ANTIBIOTIC PROPHYLAXIS; BACTERIAL PNEUMONIA; BCG VACCINATION; CD4+ T LYMPHOCYTE; DISEASE SURVEILLANCE; DRUG COST; DRUG DOSE REGIMEN; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSPOT ASSAY; EPIDEMIC; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; EXTRAPULMONARY TUBERCULOSIS; FLUORESCENCE MICROSCOPY; GASTROINTESTINAL SYMPTOM; GENE AMPLIFICATION; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; INNATE IMMUNITY; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENESIS; PERIPHERAL NEUROPATHY; POINT OF CARE TESTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; SPUTUM ANALYSIS; TH1 CELL; TUBERCULIN TEST; VIRUS TRANSMISSION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; DRUG INTERACTIONS; HUMANS; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; RIFAMYCINS; TUBERCULOSIS, PULMONARY;

EID: 79954622531     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201008-1246CI     Document Type: Review

References (144)

1. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing. WHO report 2009. Geneva, Switzerland: WHO; 2009.
2. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-1580. (Pubitemid 44780738)
3. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, Castro KG, Weyer K. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 2007;196:S86-S107. (Pubitemid 47206088)
4. Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, Willcox P, John MA, Reubenson G, Govindasamy D, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010;375:1798-1807.
5. World Health Organization. Global tuberculosis control: a short update to the 2009 report. Geneva, Switzerland: WHO; 2009.
6. Corbett EL, Bandason T, Duong T, Dauya E, Makamure B, Churchyard GJ, Williams BG, Munyati SS, Butterworth AE, Mason PR, et al. Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a clusterrandomised trial. Lancet 2010;376:1244-1253.
7. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, Walker AT, Friedland GH. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545-550. (Pubitemid 19070537)
8. Elliott AM, Halwiindi B, Hayes RJ, Luo N, Mwinga AG, Tembo G, Machiels L, Steenbergen G, Pobee JO, Nunn PP, et al. The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: two-year follow-up of a cohort in Lusaka, Zambia. J Trop Med Hyg 1995;98:9-21.
9. Glynn JR, Murray J, Bester A, Nelson G, Shearer S, Sonnenberg P. Effects of duration of HIV infection and secondary tuberculosis transmission on tuberculosis incidence in the South African gold mines. AIDS 2008;22:1859-1867.
10. Rouillon A, Perdrizet S, Parrot R. Transmission of tubercle bacilli: the effects of chemotherapy. Tubercle 1976;57:275-299.
11. Cruciani M, Malena M, Bosco O, Gatti G, Serpelloni G. The impact of human immunodeficiency virus type 1 on infectiousness of tuberculosis: a meta-analysis. Clin Infect Dis 2001;33:1922-1930. (Pubitemid 33105135)
12. Escombe AR, Moore DA, Gilman RH, Navincopa M, Ticona E, Mitchell B, Noakes C, Martinez C, Sheen P, Ramirez R, et al. Upper-room ultraviolet light and negative air ionization to prevent tuberculosis transmission. PLoS Med 2009;6:e43.
13. World Health Organization. Anti-tuberculous drug resistance in the world. Report No. 4. Geneva, Switzerland: WHO; 2008.
14. Suchindran S, Brouwer ES, Van Rie A. Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. PLoS One 2009;4:e5561.
15. Vernon A, Burman W, Benator D, Khan A, Bozeman L; Tuberculosis Trials Consortium. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999;353:1843-1847. (Pubitemid 29251017)
16. Sandman L, Schluger NW, Davidow AL, Bonk S. Risk factors for rifampin-monoresistant tuberculosis: a case-control study. Am J Respir Crit Care Med 1999;159:468-472. (Pubitemid 29084867)
17. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, Hoffner S, Drobniewski F, Barrera L, van Soolingen D, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the global project on anti-tuberculosis drug resistance surveillance. Lancet 2009;373:1861-1873.
18. van der Sande MA, Schim van der Loeff MF, Bennett RC, Dowling M, Aveika AA, Togun TO, Sabally S, Jeffries D, Adegbola RA, Sarge-Njie R, et al. Incidence of tuberculosis and survival after its diagnosis in patients infected with HIV-1 and HIV-2. AIDS 2004;18:1933-1941. (Pubitemid 39313209)
19. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005;191:150-158. (Pubitemid 40096371)
20. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002;359:2059-2064. (Pubitemid 34680968)
21. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005;19:2109-2116. (Pubitemid 41668999)
22. Miranda A, Morgan M, Jamal L, Laserson K, Barreira D, Silva G, Santos J, Wells C, Paine P, Garrett D. Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001. PLoS One 2007;2:e826.
23. Lawn SD, Bekker LG, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS 2005;19:1113-1124. (Pubitemid 41059253)
24. Girardi E, Sabin CA, d'Arminio Monforte A, Hogg B, Phillips AN, Gill MJ, Dabis F, Reiss P, Kirk O, Bernasconi E, et al. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005;41:1772-1782. (Pubitemid 41759864)
25. Bonnet MM, Pinoges LL, Varaine FF, Oberhauser BB, O'Brien DD, Kebede YY, Hewison CC, Zachariah RR, Ferradini LL. Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden. AIDS 2006;20:1275-1279. (Pubitemid 44030376)
26. Williams BG, Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 2003;301:1535-1537. (Pubitemid 37128545)
27. Lawn SD, Wood R. Tuberculosis control in South Africa-will HAART help? S Afr Med J 2006;96:502-504.
28. Toossi Z. Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. J Infect Dis 2003;188:1146-1155. (Pubitemid 37338979)
29. Nakata K, Rom WN, Honda Y, Condos R, Kanegasaki S, Cao Y, Weiden M. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med 1997;155:996-1003. (Pubitemid 27133415)
30. Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS, Munsiff SS, Ortona L, Cauda R, Fauci AS. Effect of Mycobacterium tuberculosis on HIV replication: role of immune activation. J Immunol 1996;157:1271-1278. (Pubitemid 126449644)
31. Hoshino Y, Nakata K, Hoshino S, Honda Y, Tse DB, Shioda T, Rom WN, Weiden M. Maximal HIV-1 replication in alveolar macrophages during tuberculosis requires both lymphocyte contact and cytokines. J Exp Med 2002;195:495-505. (Pubitemid 34461302)
32. + T-lymphocytopenia in severe pulmonary tuberculosis without evidence of human immunodeficiency virus infection. Int J Tuberc Lung Dis 1997;1:422-426. (Pubitemid 127509625)
33. Whalen CC, Nsubuga P, Okwera A, Johnson JL, Hom DL, Michael NL, Mugerwa RD, Ellner JJ. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS 2000;14:1219-1228. (Pubitemid 30420666)
34. Patel NR, Koziel H. Lung defenses in the immunosuppressed patient. In: Agusti C, Torres A, editors. Pulmonary infection in the immunocompromised patient. Oxford: Wiley-Blackwell; 2009.
35. Antonucci G, Girardi E, Raviglione MC, Ippolito G; Gruppo Italiano di Studio Tubercolosie AIDS (GISTA). Risk factors for tuberculosis in HIV-infected persons: a prospective cohort study. JAMA 1995;274:143-148.
36. Markowitz N, Hansen NI, Wilcosky TC, Hopewell PC, Glassroth J, Kvale PA, Mangura BT, Osmond D, Wallace JM, Rosen MJ, et al.. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons: pulmonary complications of HIV infection study group. Ann Intern Med 1993;119:185-193. (Pubitemid 23327617)
37. Zhang M, Gong J, Iyer DV, Jones BE, Modlin RL, Barnes PF. T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J Clin Invest 1994;94:2435-2442. (Pubitemid 24379619)
38. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol 2006;7:235-239.
39. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, et al.. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-1371. (Pubitemid 44924494)
40. Brenchley JM, Knox KS, Asher AI, Price DA, Kohli LM, Gostick E, Hill BJ, Hage CA, Brahmi Z, Khoruts A, et al. High frequencies of polyfunctional HIV-specific T cells are associated with preservation of mucosal CD4 T cells in bronchoalveolar lavage. Mucosal Immunol 2008;1:49-58.
41. Sutherland R, Yang H, Scriba TJ, Ondondo B, Robinson N, Conlon C, Suttill A, McShane H, Fidler S, McMichael A, et al. Impaired IFN-γ-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART. AIDS 2006;20:821-829. (Pubitemid 43731563)
42. Geldmacher C, Schuetz A, Ngwenyama N, Casazza JP, Sanga E, Saathoff E, Boehme C, Geis S, Maboko L, Singh M, et al. Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis 2008;198:1590-1598.
43. Kalsdorf B, Scriba TJ, Wood K, Day CL, Dheda K, Dawson R, Hanekom WA, Lange C, Wilkinson RJ. HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Am J Respir Crit Care Med 2009;180:1262-1270.
44. Dheda K, Chang JS, Breen RA, Haddock JA, Lipman MC, Kim LU, Huggett JF, Johnson MA, Rook GA, Zumla A. Expression of a novel cytokine, IL-4δ2, in HIV and HIV-tuberculosis co-infection. AIDS 2005;19:1601-1606. (Pubitemid 41502672)
45. Dheda K, van Zyl-Smit RN, Meldau R, Meldau S, Symons G, Khalfey H, Govender N, Rosu V, Sechi LA, Maredza A, et al. Quantitative lung T cell responses aid the rapid diagnosis of pulmonary tuberculosis. Thorax 2009;64:847-853.
46. Kaufmann SH. How can immunology contribute to the control of tuberculosis? Nat Rev Immunol 2001;1:20-30. (Pubitemid 33741972)
47. Russell DG. Mycobacterium tuberculosis: Here today, and here tomorrow. Nat Rev Mol Cell Biol 2001;2:569-577. (Pubitemid 33674008)
48. Brown CA, Draper P, Hart PD. Mycobacteria and lysosomes: a paradox. Nature 1969;221:658-660.
49. Mwandumba HC, Russell DG, Nyirenda MH, Anderson J, White SA, Molyneux ME, Squire SB. Mycobacterium tuberculosis resides in nonacidified vacuoles in endocytically competent alveolar macrophages from patients with tuberculosis and HIV infection. J Immunol 2004;172:4592-4598. (Pubitemid 38375277)
50. Keane J, Remold HG, Kornfeld H. Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages. J Immunol 2000;164:2016-2020. (Pubitemid 30108758)
51. Oddo M, Renno T, Attinger A, Bakker T, MacDonald HR, Meylan PR. Fas ligand-induced apoptosis of infected human macrophages reduces the viability of intracellular Mycobacterium tuberculosis. J Immunol 1998;160:5448-5454. (Pubitemid 28267836)
52. Schaible UE, Winau F, Sieling PA, Fischer K, Collins HL, Hagens K, Modlin RL, Brinkmann V, Kaufmann SH. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med 2003;9:1039-1046. (Pubitemid 37021784)
53. Winau F, Weber S, Sad S, de Diego J, Hoops SL, Breiden B, Sandhoff K, Brinkmann V, Kaufmann SH, Schaible UE. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 2006;24:105-117. (Pubitemid 43077204)
54. Day RB, Wang Y, Knox KS, Pasula R, Martin WJ II, Twigg HL III. Alveolar macrophages from HIV-infected subjects are resistant to Mycobacterium tuberculosis in vitro. Am J Respir Cell Mol Biol 2004;30:403-410. (Pubitemid 38315393)
55. Patel NR, Zhu J, Tachado SD, Zhang J, Wan Z, Saukkonen J, Koziel H. HIV impairs TNF-α mediated macrophage apoptotic response to Mycobacterium tuberculosis. J Immunol 2007;179:6973-6980.
56. Saukkonen JJ, Bazydlo B, Thomas M, Strieter RM, Keane J, Kornfeld H. β-Chemokines are induced by Mycobacterium tuberculosis and inhibit its growth. Infect Immun 2002;70:1684-1693.
57. 1 persons: potential role of IL-10 and BCL-3. J Leukoc Biol 2009;86:53-60.
58. Kyei GB, Dinkins C, Davis AS, Roberts E, Singh SB, Dong C, Wu L, Kominami E, Ueno T, Yamamoto A, et al. Autophagy pathway intersects with HIV-1 biosynthesis and regulates viral yields in macrophages. J Cell Biol 2009;186:255-268.
59. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004;119:753-766. (Pubitemid 40017683)
60. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004;350:2060-2067.
61. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H; Centers for Disease Control and Prevention (CDC) ; National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009;58:1-207; quiz CE201-204.
62. World Health Organization. Report of a WHO joint HIV and TB department meeting. Report from the WHO's three I's meeting: Intensified case finding (ICF), isoniazid preventative therapy (IPT) and TB infection control (IC) for people living with HIV. Geneva, Switzerland: WHO; 2008.
63. Mazurek M, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon γ release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep 2010;59:1-25.
64. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008;149:177-184.
65. Chapman AL, Munkanta M, Wilkinson KA, Pathan AA, Ewer K, Ayles H, Reece WH, Mwinga A, Godfrey-Faussett P, Lalvani A. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 2002;16:2285-2293. (Pubitemid 35449014)
66. Aichelburg MC, Rieger A, Breitenecker F, Pfistershammer K, Tittes J, Eltz S, Aichelburg AC, Stingl G, Makristathis A, Kohrgruber N. Detection and prediction of active tuberculosis disease by a wholeblood interferon-γ release assay in HIV-1-infected individuals. Clin Infect Dis 2009;48:954-962.
67. Luetkemeyer AF, Charlebois ED, Flores LL, Bangsberg DR, Deeks SG, Martin JN, Havlir DV. Comparison of an interferon-γ release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med 2007;175:737-742. (Pubitemid 46536491)
68. Talati NJ, Seybold U, Humphrey B, Aina A, Tapia J, Weinfurter P, Albalak R, Blumberg HM. Poor concordance between interferon-γ release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infect Dis 2009;9:15.
69. Rangaka MX, Wilkinson KA, Seldon R, Van Cutsem G, Meintjes GA, Morroni C, Mouton P, Diwakar L, Connell TG, Maartens G, et al. Effect of HIV-1 infection on T-cell-based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med 2007;175:514-520. (Pubitemid 46354256)
70. Dheda K, Lalvani A, Miller RF, Scott G, Booth H, Johnson MA, Zumla A, Rook GA. Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS 2005;19:2038-2041. (Pubitemid 41669032)
71. Hoffmann M, Reichmuth M, Fantelli K, Schoch OD, Fierz W, Furrer H, Vernazza P. Conventional tuberculin skin testing versus T-cell-based assays in the diagnosis of latent tuberculosis infection in HIV-positive patients. AIDS 2007;21:390-392. (Pubitemid 46175062)
72. Canadian Tuberculosis Committee. Updated recommendations on interferon γ release assays for latent tuberculosis infection: an Advisory Committee Statement (ACS). Can Commun Dis Rep 2008;34:1-13.
73. National Institute for Health and Clinical Excellence. Tuberculosis: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: Royal College of Physicians; 2006.
74. League SL. Detection of tuberculous infection by a blood-test (interferon-γ). Bern: Lungeglia Schwiez; 2005.
75. Cain KP, McCarthy KD, Heilig CM, Monkongdee P, Tasaneeyapan T, Kanara N, Kimerling ME, Chheng P, Thai S, Sar B, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med 2010;362:707-716.
76. Bassett IV, Wang B, Chetty S, Giddy J, Losina E, Mazibuko M, Bearnot B, Allen J, Walensky RP, Freedberg KA. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 2010;51:823-829.
77. Elzi L, Schlegel M, Weber R, Hirschel B, Cavassini M, Schmid P, Bernasconi E, Rickenbach M, Furrer H. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007;44:94-102. (Pubitemid 44968992)
78. Mosimaneotsile B, Mathoma A, Chengeta B, Nyirenda S, Agizew TB, Tedla Z, Motsamai OI, Kilmarx PH, Wells CD, Samandari T. Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana experience. J Acquir Immune Defic Syndr 2004-2006;54:71-77.
79. Grant AD, Charalambous S, Fielding KL, Day JH, Corbett EL, Chaisson RE, De Cock KM, Hayes RJ, Churchyard GJ. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA 2005;293:2719-2725. (Pubitemid 40965083)
80. Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, Struthers H, Gray GE, McIntyre JA, Chaisson RE, Martinson NA. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009;23:631-636.
81. Martinson NA. Novel regimens for treating latent TB in HIV-infected adults in South Africa: a randomized clinical trial. Presented at the 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, February 8-11, 2009.
82. Churchyard GJ, Fielding K, Charalambous S, Day JH, Corbett EL, Hayes RJ, Chaisson RE, De Cock KM, Samb B, Grant AD.. Efficacy of secondary isoniazid preventive therapy among HIV-infected southern Africans: time to change policy? AIDS 2003;17:2063-2070. (Pubitemid 37297154)
83. Basu S, Maru D, Poolman E, Galvani A. Primary and secondary tuberculosis preventive treatment in HIV clinics: simulating alternative strategies. Int J Tuberc Lung Dis 2009;13:652-658.
84. Hamlyn E, Childs K, Post FA. Reducing tuberculosis incidence in HIV-infected patients by tuberculin skin testing, preventive treatment, and antiretroviral therapy. Clin Infect Dis 2007;44:1393-1394; author reply 1394-1395. (Pubitemid 46717309)
85. Tedla Z, Nyirenda S, Peeler C, Agizew T, Sibanda T, Motsamai O, Vernon A, Wells CD, Samandari T. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in HIV-infected adults in Botswana. Am J Respir Crit Care Med 2010;182:278-285.
86. Pitchenik AE, Rubinson HA. The radiographic appearance of tuberculosis in patients with the acquired immune deficiency syndrome (AIDS) and pre-AIDS. Am Rev Respir Dis 1985;131:393-396. (Pubitemid 15133600)
87. Lee MP, Chan JW, Ng KK, Li PC. Clinical manifestations of tuberculosis in HIV-infected patients. Respirology 2000;5:423-426. (Pubitemid 32049509)
88. Huebner RE, Castro KG. The changing face of tuberculosis. Annu Rev Med 1995;46:47-55.
89. Huang L, Crothers K. HIV-associated opportunistic pneumonias. Respirology 2009;14:474-485.
90. Goodman PC. Tuberculosis and AIDS. Radiol Clin North Am 1995;33:707-717.
91. Perkins MD, Cunningham J. Facing the crisis: improving the diagnosis of tuberculosis in the HIV era. J Infect Dis 2007;196:S15-S27. (Pubitemid 47206081)
92. Monkongdee P, McCarthy KD, Cain KP, Tasaneeyapan T, Nguyen HD, Nguyen TN, Nguyen TB, Teeratakulpisarn N, Udomsantisuk N, Heilig C, et al. Yield of acid-fast smear and mycobacterial culture for tuberculosis diagnosis in people with human immunodeficiency virus. Am J Respir Crit Care Med 2009;180:903-908.
93. Whalen C, Horsburgh CR Jr, Hom D, Lahart C, Simberkoff M, Ellner J. Site of disease and opportunistic infection predict survival in HIV-associated tuberculosis. AIDS 1997;11:455-460. (Pubitemid 27113006)
94. Kivihya-Ndugga LE, van Cleeff MR, Githui WA, Nganga LW, Kibuga DK, Odhiambo JA, Klatser PR. A comprehensive comparison of Ziehl-Neelsen and fluorescence microscopy for the diagnosis of tuberculosis in a resource-poor urban setting. Int J Tuberc Lung Dis 2003;7:1163-1171. (Pubitemid 38004740)
95. Prasanthi K, Kumari AR. Efficacy of fluorochrome stain in the diagnosis of pulmonary tuberculosis co-infected with HIV. Indian J Med Microbiol 2005;23:179-181. (Pubitemid 41188492)
96. Singh NP, Parija SC. The value of fluorescence microscopy of auramine stained sputum smears for the diagnosis of pulmonary tuberculosis. Southeast Asian J Trop Med Public Health 1998;29:860-863. (Pubitemid 128709203)
97. Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J, Urbanczik R, Perkins M, Aziz MA, Pai M. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006;6:570-581. (Pubitemid 44262344)
98. Steingart KR, Ng V, Henry M, Hopewell PC, Ramsay A, Cunningham J, Urbanczik R, Perkins MD, Aziz MA, Pai M. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006;6:664-674. (Pubitemid 44462695)
99. Bonnet M, Ramsay A, Githui W, Gagnidze L, Varaine F, Guerin PJ. Bleach sedimentation: an opportunity to optimize smear microscopy for tuberculosis diagnosis in settings of high prevalence of HIV. Clin Infect Dis 2008;46:1710-1716. (Pubitemid 351706768)
100. Eyangoh SI, Torrea G, Tejiokem MC, Kamdem Y, Piam FF, Noeske J, Van Deun A. HIV-related incremental yield of bleach sputum concentration and fluorescence technique for the microscopic detection of tuberculosis. Eur J Clin Microbiol Infect Dis 2008;27:849-855.
101. Lawson L, Yassin MA, Ramsay A, Emenyonu EN, Thacher TD, Davies PD, Squire SB, Cuevas LE. Short-term bleach digestion of sputum in the diagnosis of pulmonary tuberculosis in patients coinfected with HIV. Tuberculosis (Edinb) 2007;87:368-372. (Pubitemid 46936243)
102. Ramsay A, Yassin MA, Cambanis A, Hirao S, Ahmad A, Mohamed G, Lovett L, Arbide I, Al-Aghbari N, Al-Sonboli N, et al. Front-loading sputum microscopy services: an opportunity to optimise smear-based case detection of tuberculosis in high prevalence countries. J Trop Med 2009;2009:1-6.
103. Diraa O, Fdany K, Boudouma M, Elmdaghri N, Benbachir M. Assessment of the mycobacteria growth indicator tube for the bacteriological diagnosis of tuberculosis. Int J Tuberc Lung Dis 2003;7:1010-1012. (Pubitemid 37237066)
104. Tortoli E, Cichero P, Piersimoni C, Simonetti MT, Gesu G, Nista D. Use of BACTEC MGIT 960 for recovery of mycobacteria from clinical specimens: multicenter study. J Clin Microbiol 1999;37:3578-3582. (Pubitemid 29491095)
105. Venkataraman P, Herbert D, Paramasivan CN. Evaluation of the BACTEC radiometric method in the early diagnosis of tuberculosis. Indian J Med Res 1998;108:120-127. (Pubitemid 28479413)
106. Johnson JL, Vjecha MJ, Okwera A, Hatanga E, Byekwaso F, Wolski K, Aisu T, Whalen CC, Huebner R, Mugerwa RD, et al. Impact of human immunodeficiency virus type-1 infection on the initial bacteriologic and radiographic manifestations of pulmonary tuberculosis in Uganda: Makerere University-Case Western Reserve University research collaboration. Int J Tuberc Lung Dis 1998;2:397-404. (Pubitemid 28239862)
107. Dinnes J, Deeks J, Kunst H, Gibson A, Cummins E, Waugh N, Drobniewski F, Lalvani A. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess 2007;11:1-196.
108. Kivihya-Ndugga L, van Cleeff M, Juma E, Kimwomi J, Githui W, Oskam L, Schuitema A, van Soolingen D, Nganga L, Kibuga D, et al. Comparison of PCR with the routine procedure for diagnosis of tuberculosis in a population with high prevalences of tuberculosis and human immunodeficiency virus. J Clin Microbiol 2004;42:1012-1015. (Pubitemid 38332818)
109. Shah M, Variava E, Holmes CB, Coppin A, Golub JE, McCallum J, Wong M, Luke B, Martin DJ, Chaisson RE, et al. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a high HIV prevalence setting. J Acquir Immune Defic Syndr 2009;52:145-151.
110. Dheda K, Davids V, Lenders L, Roberts T, Meldau R, Ling D, Brunet L, van Zyl Smit R, Peter J, Green C, et al. Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples. PLoS One 2010;5:e9848.
111. Steingart KR, Henry M, Laal S, Hopewell PC, Ramsay A, Menzies D, Cunningham J, Weldingh K, Pai M. Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review. PLoS Med 2007;4:e202.
112. Moore DA, Evans CA, Gilman RH, Caviedes L, Coronel J, Vivar A, Sanchez E, Pinedo Y, Saravia JC, Salazar C, et al. Microscopicobservation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006;355:1539-1550.
113. Reddy KP, Brady MF, Gilman RH, Coronel J, Navincopa M, Ticona E, Chavez G, Sanchez E, Rojas C, Solari L, et al. Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons. Clin Infect Dis 2010;50:988-996.
114. Minion J, Leung E, Menzies D, Pai M. Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2010;10:688-698.
115. World Health Organization. Non-commercial culture and drug-susceptibility testing methods for screening of patients at risk of multi-drug resistant tuberculosis. Geneva, Switzerland: WHO; 2010.
116. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. Geneva, Switzerland: WHO; 2009.
117. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a highvolume public health laboratory in South Africa. Am J Respir Crit Care Med 2008;177:787-792. (Pubitemid 351490566)
118. Luo RF, Scahill MD, Banaei N. Comparison of single-copy and multicopy real-time PCR targets for detection of Mycobacterium tuberculosis in paraffin-embedded tissue. J Clin Microbiol 2010;48:2569-2570.
119. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010;363:1005-1015.
120. Nachega JB, Maartens G. Clinical aspects of tuberculosis in HIV-infected adults. In: Schaaf HS, Zumla AI, editors. Tuberculosis-a comprehensive clinical reference, 1st ed. St. Louis, MO: Elsevier; 2009.
121. Corbett EL, Marston B, Churchyard GJ, De Cock KM. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006;367:926-937.
122. Korenromp EL, Scano F, Williams BG, Dye C, Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin Infect Dis 2003;37:101-112. (Pubitemid 36836652)
123. Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, Menzies D. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010;50:1288-1299.
124. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004;364:1244-1251. (Pubitemid 39311345)
125. Driver CR, Munsiff SS, Li J, Kundamal N, Osahan SS. Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City. Clin Infect Dis 2001;33:1762-1769. (Pubitemid 33044545)
126. Nahid P, Gonzalez LC, Rudoy I, de Jong BC, Unger A, Kawamura LM, Osmond DH, Hopewell PC, Daley CL. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007;175:1199-1206. (Pubitemid 46855463)
127. Perriens JH, St Louis ME, Mukadi YB, Brown C, Prignot J, Pouthier F, Portaels F, Willame JC, Mandala JK, Kaboto M, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995;332:779-784.
128. Swaminathan S, Narendran G, Venkatesan P, Iliayas S, Santhanakrishnan R, Menon PA, Padmapriyadarsini C, Ramachandran R, Chinnaiyan P, Suhadev M, et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med 2010;181:743-751.
129. World Health Organization. Treatment of tuberculosis guidelines. Geneva, Switzerland: WHO; 2010.
130. Marks DJ, Dheda K, Dawson R, Ainslie G, Miller RF. Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs. Int J STD AIDS 2009;20:339-345.
131. Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med 2007;4:e238.
132. Burman WJ. Drug interactions in the treatment of HIV-related tuberculosis. In: Schaaf HS, Zumla AI, editors. Tuberculosis-a comprehensive clinical reference, 1st ed. St. Louis, MO: Elsevier; 2009.
133. Alcorn K. Second-line treatment: Clinton Foundation announces new price cut [Internet; accessed January 2011]. Available from: http://www.aidsmap. com/news/Second-line-treatment-Clinton-Foundationannounces-new-price-cut/page/ 1435524/.
134. Dhasmana DJ, Dheda K, Ravn P, Wilkinson RJ, Meintjes G. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs 2008;68:191-208.
135. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, Elliott JH, Murdoch D, Wilkinson RJ, Seyler C, et al. Tuberculosisassociated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008;8:516-523. (Pubitemid 352005824)
136. Meintjes G, Rangaka MX, Maartens G, Rebe K, Morroni C, Pepper DJ, Wilkinson KA, Wilkinson RJ. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis 2009;48:667-676.
137. Meintjes G, Wilkinson RJ, Morroni C, Pepper DJ, Rebe K, Rangaka MX, Oni T, Maartens G. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010;24:2381-2390.
138. Harries AD, Zachariah R, Lawn SD. Providing HIV care for coinfected tuberculosis patients: a perspective from sub-Saharan Africa. Int J Tuberc Lung Dis 2009;13:6-16.
139. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendation for a public health approach. Geneva, Switzerland: WHO; 2010.
140. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010;362:697-706.
141. Blanc FX, Havlir DV, Onyebujoh PC, Thim S, Goldfeld AE, Delfraissy JF. Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials. J Infect Dis 2007;196:S46-S51. (Pubitemid 47206084)
142. Pathak SK, Basu S, Bhattacharyya A, Pathak S, Kundu M, Basu J. Mycobacterium tuberculosis lipoarabinomannan-mediated IRAK-M induction negatively regulates Toll-like receptor-dependent interleukin-12 p40 production in macrophages. J Biol Chem 2005;280:42794-42800. (Pubitemid 43049241)
143. Via LE, Fratti RA, McFalone M, Pagan-Ramos E, Deretic D, Deretic V. Effects of cytokines on mycobacterial phagosome maturation. J Cell Sci 1998;111:897-905. (Pubitemid 28196073)
144. Lalvani A, Hingley-Wilson S. Editorial: Live or let die-does HIV exacerbate tuberculosis by attenuating M. tuberculosis-induced apoptosis? J Leukoc Biol 2009;86:9-11.